Full-Time

Director Information Security

GCC India & JAPAC

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

No salary listed

Hyderabad, Telangana, India

Hybrid

Hybrid role in Hyderabad.

Bachelor's

Category
IT & Security (1)
Required Skills
LLM
Incident Response
Vulnerability Analysis
SOC 2
SCRUM
HIPAA

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in Computer Science, Information Technology, Cybersecurity, Engineering, or a related discipline is required.
  • Significant leadership experience managing enterprise Information Security organizations within global companies is required.
  • Deep expertise across cyber operations, incident response, cyber risk and assurance, data protection, AI security, security architecture, identity and access management, vulnerability management, and attack surface management is required.
  • Demonstrated success leading security engineering, operations, architecture, and delivery teams in complex global environments is required.
  • Experience with modern security technologies including SIEM/SOAR, EDR/XDR, cloud security, IAM/PAM, DLP, and vulnerability management platforms is required.
  • Strong knowledge of security frameworks and regulations including NIST CSF, ISO 27001, SOC 2, GDPR, HIPAA, SOX IT controls, and GxP data integrity requirements is required.
  • Experience evaluating, implementing, and governing AI and GenAI security capabilities within regulated environments is required.
  • A proven track record of building, scaling, and retaining high-performing technical organizations is required.
  • Experience establishing or significantly expanding Global Capability Center operations, including workforce transformation and organizational growth initiatives, is required.
  • Strong strategic planning, business insight, and decision-making skills are required, with the ability to translate ambiguity into actionable security strategies.
  • Exceptional written, verbal, and executive communication skills are required, with experience engaging senior collaborators across multiple geographies and cultures.
  • Familiarity with APAC information security and privacy regulations, including India's Digital Personal Data Protection Act and related regional requirements, is required.
  • Experience within pharmaceutical, biotechnology, life sciences, or other highly regulated industries is required.
  • Experience operating security programs across multiple jurisdictions and compliance frameworks simultaneously is required.
Responsibilities
  • Build, lead, and scale the India GCC Information Security organization, fostering a high-performance, inclusive culture focused on accountability, innovation, and continuous improvement.
  • Provide leadership across Cyber Operations, Cyber Risk & Assurance, Data Protection & AI Security, Security Architecture, Identity & Access Management, and Attack Surface Management.
  • Lead end-to-end delivery across security engineering, operations, architecture, and data teams using agile and traditional delivery models.
  • Drive adoption and optimization of SIEM/SOAR, EDR/XDR, cloud-native security platforms, IAM/PAM, DLP, and vulnerability management solutions.
  • Establish the India GCC security organization as a strategic extension of the global security team, ensuring operational excellence, delivery predictability, and continuous process improvement.
  • Lead recruiting, onboarding, workforce planning, contractor-to-FTE conversions, and capability expansion across security functions.
  • Serve as the JAPAC Information Security lead, representing Regeneron's security posture to business, regulatory, and partner collaborators throughout the Asia-Pacific region.
  • Design and oversee security governance, risk management, compliance, and control assurance programs aligned with industry frameworks and regulatory requirements.
  • Ensure continuous audit, inspection, and compliance readiness across security programs and technology environments.
  • Partner with executive leaders to translate business objectives into security strategies, investment priorities, and organizational initiatives.
  • Communicate complex security, technology, regulatory, and risk matters to executive, board-level, and operational audiences with clarity and credibility.
  • Evaluate and govern AI and GenAI capabilities to enhance security operations while maintaining compliance, privacy, and governance standards.
Desired Qualifications
  • Relevant certifications such as CISSP, CISM, CISA, CCSP, PMP, SAFe, Scrum, or cloud security certifications.
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 17% to $4.3 billion, with EPS beating estimates.
  • Sanofi development balance was fully repaid, improving future collaboration economics.
  • Regeneron held $15.1 billion net cash and repurchased $2.0 billion in 2026.

What critics are saying

  • May 15, 2026 fianlimab-Libtayo failed its melanoma primary endpoint, crushing pipeline credibility.
  • Securities class action No. 26-cv-6026 targets Regeneron through September 14, 2026.
  • Itepekimab's inconsistent COPD data from ATS 2026 threatens future respiratory approvals.

What makes Regeneron Pharmaceuticals unique

  • Dupixent, co-marketed with Sanofi, drove $6.0 billion Q2 2026 sales.
  • EYLEA HD gained FDA approval April 2, 2026 for 20-week dosing.
  • Libtayo reached record $489 million global sales in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
The Mirror Democrat and Savanna Times-Journal
Aug 2nd, 2026
Bronstein, Gewirtz & Grossman LLC urges Regeneron Pharmaceuticals, Inc. investors to act: Class Action filed alleging investor harm.

Bronstein, Gewirtz & Grossman LLC urges Regeneron Pharmaceuticals, Inc. investors to act: Class Action filed alleging investor harm. * 4 hrs ago NEW YORK, Aug. 02, 2026 (GLOBE NEWSWIRE) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REGN. Regeneron Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: * the preliminary statistical assumptions underlying Regeneron's Phase III Fianlimab-Libtayo study were fundamentally flawed; * the study's active treatment arm was not demonstrating meaningful clinical differentiation from standard therapies; * the study was unlikely to achieve statistical significance with respect to its primary endpoint, even absent overperformance by the control arm; and * as a result, the Company's statements regarding the study's design, progress, and prospects were materially false and/or misleading at all relevant times. What's Next for Regeneron Investors? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REGN. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Regeneron you have until September 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. No Cost to Regeneron Investors Mycarrollcountynews, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means Mycarrollcountynews will ask the court to reimburse Mycarrollcountynews for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if Mycarrollcountynews is successful. Why Bronstein, Gewirtz & Grossman, LLC for Regeneron Securities Class Action? Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Its firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC. Contact Info Peretz Bronstein, Esq. or Nathan Miller Bronstein, Gewirtz & Grossman, LLC Attorney advertising. Prior results do not guarantee similar outcomes.

Mangalore Mirror
Jul 31st, 2026
REGN ALERT: Hagens Berman alerts Regeneron Pharmaceuticals, Inc. (REGN) investors to pending Securities Class Action amid disclosures about key trial's protocol and ultimate failure.

REGN ALERT: Hagens Berman alerts Regeneron Pharmaceuticals, Inc. (REGN) investors to pending Securities Class Action amid disclosures about key trial's protocol and ultimate failure. 2 3 minutes read SAN FRANCISCO, July 30, 2026 (GLOBE NEWSWIRE) - Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. Discover more Engineering & Technology Android OS Printing & Publishing The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026. National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys. Class Period: Aug. 1, 2025 - May 15, 2026 Lead Plaintiff Deadline: Sept. 14, 2026 Visit: http://www.hbsslaw.com/investor-fraud/regn Contact the Firm Now: [email protected] 844-916-0895 Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron's repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the "Study"). The Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" - disease progression or death - determined the timing and statistical power of the primary PFS analysis. The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely. Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial's achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are "because the test arms are performing well." The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that "t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months." One prominent analyst reportedly questioned whether the decision was made because, in contrast to management's expressed confidence, the "underlying PFS benefit may be insufficient to show statistical significance." Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to "slow event rates," occurred nearly six months ago, and was "submitted it to all the global regulatory authorities in November, December timeframe." Discover more Visual Art & Design Geographic Reference Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the "trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS)." "We're focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn't really there," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit. If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now" If you'd like more information and answers to other frequently asked questions about the Regeneron case and the firm's investigation, read more" Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Today in New York
Jul 31st, 2026
$REGN securities: suffer losses on your Regeneron investment? BFA Law reminds investors of the Securities Fraud lawsuit to recover losses.

$REGN securities: suffer losses on your Regeneron investment? BFA Law reminds investors of the Securities Fraud lawsuit to recover losses. A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial. NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Regeneron, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/regeneron-class-action-lawsuit. Key Details of the Regeneron ($REGN) Class Action: * Lead Plaintiff Deadline: September 14, 2026 * Alleged Misconduct: Securities fraud alleging that Regeneron misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial * Stock Drop: * April 29, 2026 - 6.2% Stock Drop * May 15, 2026 - 9.8% Stock Drop * Court: U.S. District Court for the Southern District of New York * Action: Contact BFA Law to discuss your rights Investors have until September 14, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Regeneron securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Cheathem v. Regeneron Pharm., Inc., et al., No. 26-cv-6026. Why is Regeneron Being Sued for Securities Fraud? Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders. During the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Specifically, Regeneron was testing Fianlimab in combination with Libtayo in a Phase III study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma. Regeneron told investors that it had "a lot of hope and confidence" that the Phase III trial "can generate a meaningful differentiation against current standards of care." Further, despite acknowledging that study results had slowed, Regeneron told investors that this was likely because "there was a high level of response and those response[s] are very durable" and that the combination drug was a "potential blockbuster." In truth, as alleged, the Phase III Fianlimab-Libtayo study did not achieve statistically significant results. Why did Regeneron's Stock Drop? On April 29, 2026, before market hours, Regeneron announced the Phase III Fianlimab-Libtayo study "will now consider all patients enrolled in the study with a minimum follow-up of 6 months." This expansion of the study parameters indicated the study did not have enough positive results to achieve statistical significance. This news caused the price of Regeneron stock to decline $45.41 per share, or 6.2%, from a closing price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026. Then, on May 15, 2026, after market hours, Regeneron published a press release stating that the Phase III Fianlimab-Libtayo "did not reach statistical significance for the primary endpoint" tested. This news caused the price of Regeneron stock to decline $68.57 per share, or 9.8%, from a closing price of $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026. What Can You Do? If you invested in Regeneron, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Today in New York do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MarketBeat
Jul 30th, 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announces quarterly dividend of $0.94.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announces quarterly dividend of $0.94. July 30, 2026 Key points. * Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The annualized dividend is $3.76, representing a 0.5% yield and a low 9.6% payout ratio. * Regeneron reported quarterly EPS of $14.29, exceeding analyst expectations of $10.16, while revenue reached $4.29 billion versus the $3.82 billion consensus estimate. Revenue increased 16.7% year over year. * Shares rose 6.2% to $738.34 during Thursday trading, though the stock remains below its 12-month high of $821.11. Institutional investors own approximately 83.31% of the company. * Five stocks to consider instead of Regeneron Pharmaceuticals. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) declared a quarterly dividend on Thursday, July 30th. Investors of record on Tuesday, August 18th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Monday, August 31st. This represents a c) dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals has a payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Regeneron Pharmaceuticals to earn $42.26 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 8.9%. Regeneron Pharmaceuticals stock up 6.2%. Shares of REGN stock traded up $42.92 during trading hours on Thursday, hitting $738.34. 1,460,610 shares of the company's stock traded hands, compared to its average volume of 859,543. The stock's fifty day simple moving average is $638.74 and its two-hundred day simple moving average is $711.76. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $821.11. The stock has a market cap of $78.06 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 27.77 and a beta of 0.24. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.81 EPS. On average, analysts expect that Regeneron Pharmaceuticals will post 2.06 EPS for the current year. Insider buying and selling. In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company's stock. Institutional inflows and outflows. Several institutional investors have recently made changes to their positions in REGN. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $1,012,296,000. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company's stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares in the last quarter. Nuveen LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the period. Wellington Management Group LLP boosted its position in shares of Regeneron Pharmaceuticals by 8,620.0% in the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company's stock worth $512,881,000 after purchasing an additional 656,845 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 528.7% in the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company's stock worth $405,596,000 after purchasing an additional 606,612 shares in the last quarter. Institutional investors own 83.31% of the company's stock. About Regeneron Pharmaceuticals. Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas. Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Regeneron Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list. While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

PR Newswire
Jul 27th, 2026
Regeneron Pharmaceuticals (NASDAQ: REGN) investors who suffered losses May Be Eligible to participate in the securities Class Action; contact Robbins LLP for information about recovering your losses.

Regeneron Pharmaceuticals (NASDAQ: REGN) investors who suffered losses May Be Eligible to participate in the securities Class Action; contact Robbins LLP for information about recovering your losses. Jul 27, 2026, 17:33 ET Lead Plaintiff Deadline: September 14, 2026 SAN DIEGO, July 27, 2026 /PRNewswire/ - Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"). The lawsuit alleges that Regeneron Pharmaceuticals misled investors regarding the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for patients with advanced melanoma. Investors who suffered losses during the Class Period may have legal rights and should be aware of the September 14, 2026 deadline to seek appointment as lead plaintiff. Why Was Regeneron Sued? According to the complaint, Regeneron was developing Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Fianlimab was being evaluated in combination with Libtayo in a Phase 3 clinical trial investigating whether the combination could serve as a first-line treatment for patients with advanced melanoma. The Phase 3 Fianlimab-Libtayo study began enrolling patients in mid-2022. The complaint alleges that Regeneron provided investors with positive statements about the study while failing to disclose material information concerning its prospects. Specifically, plaintiff alleges that Regeneron failed to disclose that: * the study's preliminary statistical assumptions were fundamentally flawed; * the Fianlimab-Libtayo treatment arm was failing to achieve meaningful clinical differentiation from standard therapies; and * the trial was ultimately unlikely to achieve statistical significance on its primary endpoint, even without unusually strong performance by the control arm. The complaint alleges that these omissions caused Regeneron's stock to trade at artificially inflated prices. What Happened to Regeneron Stock? According to the complaint, information concerning the Phase 3 Fianlimab-Libtayo study emerged through a series of disclosures in April and May 2026. April 29, 2026: Regeneron Discloses Changes to the Phase 3 Study On April 29, 2026, during Regeneron's first-quarter earnings call, defendants disclosed that the Phase 3 Fianlimab-Libtayo study had been modified to expand the number of patients eligible for analysis of progression-free survival (PFS). Following the disclosure, Regeneron's stock price fell from $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026, a decline of approximately 6.2% in a single trading day. May 15, 2026: Fianlimab-Libtayo Trial Fails to Meet Primary Endpoint After the market closed on May 15, 2026, Regeneron announced that its Phase 3 Fianlimab trial did not achieve statistical significance for the primary endpoint of improvement in progression-free survival. Following the announcement, Regeneron's stock price declined from $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026, a decline of approximately 9.8%. The complaint alleges that these disclosures revealed information that contradicted or called into question Regeneron's prior statements concerning the clinical trial. What Is the Regeneron Fianlimab-Libtayo Class Action About? The lawsuit alleges that Regeneron failed to disclose material information concerning the viability of its Phase 3 Fianlimab-Libtayo study. According to the complaint, investors were not adequately informed about alleged problems with the study's statistical assumptions, the lack of meaningful clinical differentiation between the treatment and control arms, and the alleged risk that the trial would fail to meet its primary endpoint. The lawsuit seeks damages on behalf of investors who purchased Regeneron securities during the Class Period. What Is Fianlimab? Fianlimab is a monoclonal antibody that targets the LAG-3 immune checkpoint receptor on T-cells. Regeneron was studying Fianlimab in combination with Libtayo in a Phase 3 trial involving patients with advanced melanoma. The lawsuit centers on allegations concerning the clinical trial's design, statistical assumptions, efficacy results, and ultimate failure to meet its primary progression-free survival endpoint. What Is Progression-Free Survival? Progression-free survival (PFS) is a clinical-trial endpoint that measures the length of time patients remain alive without their disease worsening or progressing. The complaint alleges that the Fianlimab-Libtayo Phase 3 study failed to achieve statistical significance for its primary PFS endpoint. Who May Be Eligible? The proposed class includes investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026. If you purchased REGN securities during this period and suffered losses, you may have rights under the federal securities laws. What Is a Lead Plaintiff? The lead plaintiff is an investor appointed by the court to represent the interests of the proposed class throughout the litigation. Investors do not have to serve as lead plaintiff to potentially share in any future recovery if the lawsuit is successful. The deadline to seek appointment as lead plaintiff is September 14, 2026. Frequently Asked Questions What is the Regeneron class action about? The lawsuit alleges that Regeneron Pharmaceuticals misled investors about the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma. Why did Regeneron stock fall in April 2026? According to the complaint, Regeneron disclosed on April 29, 2026 that the Phase 3 Fianlimab-Libtayo study had been modified to expand the number of patients eligible for analysis of progression-free survival. Regeneron's stock declined approximately 6.2% that day. Why did Regeneron stock fall in May 2026? After the market closed on May 15, 2026, Regeneron announced that the Phase 3 Fianlimab trial did not achieve statistical significance for the primary endpoint of improvement in progression-free survival. The stock subsequently declined approximately 9.8% from May 15 to May 18. Did the Fianlimab-Libtayo trial succeed? According to Regeneron's May 15, 2026 announcement as described in the complaint, the Phase 3 trial did not reach statistical significance for its primary endpoint of improvement in progression-free survival. Who can participate in the Regeneron lawsuit? Investors who purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026 may be eligible to participate in the proposed securities class action. Do I have to become lead plaintiff? No. Investors do not have to seek appointment as lead plaintiff to potentially share in any future recovery if the litigation is successful. Does it cost anything to participate? Robbins LLP represents investors on a contingency fee basis. Investors never pay no attorneys' fees or litigation expenses. If there is a recovery for shareholders, defendants pay attorneys' fees and expenses. Contact Robbins LLP Investors seeking additional information about the Regeneron securities class action may submit an inquiry through Robbins LLP's website, email attorney Aaron Dumas, Jr., or call (800) 350-6003. About Robbins LLP A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies. "Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP. To be notified if a class action against Regeneron Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP